Efficacy, safety, and durability of long-acting cabotegravir and rilpivirine in adults with human immunodeficiency virus type 1 infection: 5-year results from the LATTE-2 …
GHR Smith, WK Henry, D Podzamczer… - Open Forum …, 2021 - academic.oup.com
Abstract Background In the Long-Acting Antiretroviral Treatment Enabling Trial 2 (LATTE-2)
phase 2b study, long-acting (LA) injectable cabotegravir+ rilpivirine dosed every 8 weeks …
phase 2b study, long-acting (LA) injectable cabotegravir+ rilpivirine dosed every 8 weeks …
Long-acting cabotegravir and rilpivirine dosed every 2 months in adults with human immunodeficiency virus 1 type 1 infection: 152-week results from ATLAS-2M, a …
ET Overton, G Richmond, G Rizzardini… - Clinical Infectious …, 2023 - academic.oup.com
Abstract Background Cabotegravir (CAB)+ rilpivirine (RPV) dosed intramuscularly monthly
or every 2 months is a complete, long-acting (LA) regimen for the maintenance of HIV-1 …
or every 2 months is a complete, long-acting (LA) regimen for the maintenance of HIV-1 …
Initiation of long-acting cabotegravir plus rilpivirine as direct-to-injection or with an oral lead-in in adults with HIV-1 infection: week 124 results of the open-label phase …
Background Previous work established non-inferiority of switching participants who were
virologically suppressed from daily oral standard of care to monthly long-acting …
virologically suppressed from daily oral standard of care to monthly long-acting …
Long-acting cabotegravir plus rilpivirine for treatment in adults with HIV-1 infection: 96-week results of the randomised, open-label, phase 3 FLAIR study
Background There is a need for more convenient, less frequent treatment to help address
challenges associated with daily oral HIV treatment in people living with HIV, including …
challenges associated with daily oral HIV treatment in people living with HIV, including …
Long-acting cabotegravir and rilpivirine dosed every 2 months in adults with HIV-1 infection (ATLAS-2M), 96-week results: a randomised, multicentre, open-label …
H Jaeger, ET Overton, G Richmond, G Rizzardini… - The Lancet …, 2021 - thelancet.com
Background Long-acting cabotegravir and rilpivirine administered monthly or every 2
months might address the challenges associated with daily oral antiretroviral therapy. The …
months might address the challenges associated with daily oral antiretroviral therapy. The …
[HTML][HTML] Long-acting injectable cabotegravir+ rilpivirine for HIV maintenance therapy: week 48 pooled analysis of phase 3 ATLAS and FLAIR trials
G Rizzardini, ET Overton, C Orkin… - JAIDS Journal of …, 2020 - journals.lww.com
Background: Long-acting (LA) injectable regimens are a potential therapeutic option in
people living with HIV-1. Setting: ATLAS (NCT02951052) and FLAIR (NCT02938520) were …
people living with HIV-1. Setting: ATLAS (NCT02951052) and FLAIR (NCT02938520) were …
Cabotegravir/Rilpivirine: the last FDA-approved drug to treat HIV
Introduction The development of long-acting (LA) drugs has changed the management of
common medical conditions for human replication immunodeficiency virus (HIV). Cabenuva …
common medical conditions for human replication immunodeficiency virus (HIV). Cabenuva …
Long-acting cabotegravir and rilpivirine dosed every 2 months in adults with HIV-1 infection (ATLAS-2M), 48-week results: a randomised, multicentre, open-label …
ET Overton, G Richmond, G Rizzardini, H Jaeger… - The Lancet, 2020 - thelancet.com
Background Phase 3 clinical studies showed non-inferiority of long-acting intramuscular
cabotegravir and rilpivirine dosed every 4 weeks to oral antiretroviral therapy. Important …
cabotegravir and rilpivirine dosed every 4 weeks to oral antiretroviral therapy. Important …
[HTML][HTML] Week 96 extension results of a phase 3 study evaluating long-acting cabotegravir with rilpivirine for HIV-1 treatment
S Swindells, T Lutz, L Van Zyl, N Porteiro, M Stoll… - Aids, 2022 - journals.lww.com
Background: ATLAS (NCT02951052), a phase 3, multicenter, open-label study,
demonstrated that switching to injectable cabotegravir (CAB) with rilpivirine (RPV) long …
demonstrated that switching to injectable cabotegravir (CAB) with rilpivirine (RPV) long …
Patient-reported tolerability and acceptability of cabotegravir+ rilpivirine long-acting injections for the treatment of HIV-1 infection: 96-week results from the randomized …
M Murray, F Pulido, A Mills, M Ramgopal… - HIV Research & …, 2019 - Taylor & Francis
Background: Long-acting (LA) injectable antiretroviral therapy (ART) is a novel modality
currently under development as an alternative to daily oral ART. Objective: The LATTE-2 …
currently under development as an alternative to daily oral ART. Objective: The LATTE-2 …